Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Salivary Gland Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Iodine-131 21lenvatinib 17Magnetic Resonance Spectroscopy 17trametinib 13Sorafenib 13Thyrotropin Alfa 12pembrolizumab 11dabrafenib 11Thyroidectomy 10Surgical Procedures, Operative 10Thyroxine 9Paclitaxel 9vandetanib 8selpercatinib 8Sunitinib 7Nivolumab 7Fluorodeoxyglucose F18 7cabozantinib 6anlotinib 6Everolimus 6Biopsy 6pazopanib 5Vemurafenib 5Triiodothyronine 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Iodine-124 5Cyclophosphamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Pharmacogenomic Testing × Head & Neck × Clear all
NCT00381641 2025-03-28

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
63 enrolled 12 charts
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡